Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VVOS Vivos Therapeutics

Post-Mkt 05-19 19:02:30 EDT

0.5851

-0.0139

-2.32%

盘后0.5851

+0.00000.00%

16:04 EDT

High0.6500	Low0.5800	Vol55.27K
Open0.5940	D1 Closing0.5990	Amplitude11.69%
Mkt Cap8.02M	Tradable Cap7.46M	Total Shares13.71M
T/O33.19K	T/O Rate0.43%	Tradable Shares12.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VVOS","market":"US","secType":"STK","nameCN":"Vivos Therapeutics","latestPrice":0.5851,"timestamp":1779220800000,"preClose":0.599,"halted":0,"volume":55267,"hourTrading":{"tag":"盘后","latestPrice":0.5851,"preClose":0.5851,"latestTime":"16:04 EDT","volume":3,"amount":1.7552999999999999,"timestamp":1779221094434,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.023205342237061808,"floatShares":12753900,"shares":13714300,"eps":-2.07,"marketStatus":"Post-Mkt","change":-0.0139,"latestTime":"05-19 19:02:30 EDT","open":0.594,"high":0.65,"low":0.58,"amount":33188.004359,"amplitude":0.116861,"askPrice":0.61,"askSize":1,"bidPrice":0.57,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.07,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1779235200000},"marketStatusCode":4,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":0.599,"preHourTrading":{"tag":"盘前","latestPrice":0.6072,"preClose":0.599,"latestTime":"08:44 EDT","volume":633,"amount":397.81819307999996,"timestamp":1779194664121,"change":0.0082,"changeRate":0.013689,"amplitude":0.10985},"postHourTrading":{"tag":"盘后","latestPrice":0.5851,"preClose":0.5851,"latestTime":"16:04 EDT","volume":3,"amount":1.7552999999999999,"timestamp":1779221094434,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.381928,"impliedVol":2.594,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/VVOS","defaultTab":"news","newsList":[{"id":"2635552056","title":"Vivos Therapeutics Delays Quarterly Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635552056","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635552056?lang=en_us&edition=fundamental","pubTime":"2026-05-16 07:35","pubTimestamp":1778888133,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics ( ($VVOS) ) has released a notification of late filing. Vivos Therapeutics, Inc. has filed a Form 12b-25 to notify investors of ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-delays-quarterly-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-delays-quarterly-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037992","title":"Vivos Therapeutics delays Q1 10-Q filing, seeks SEC extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037992","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037992?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:08","pubTimestamp":1778875713,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics filed a Form 12b-25 to delay its quarterly report for period ended March 31, 2026.Filing cited need for more time to complete review of interim financial statements for Sleep Center of Nevada, acquired in 2025, before consolidating results into company unaudited financials.Company expects to file Form 10-Q within five-calendar-day extension under SEC Rule 12b-25.Revenue seen up about 70% year over year, gross profit up about 100%, driven by added patient product and service sales from SCN operations.Sales, general, and administrative expenses expected to rise about 70%, with net loss projected to widen versus prior-year quarter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the orig","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL1THF2C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634258636","title":"Vivos Therapeutics Inc  expected to post a loss of 45 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634258636","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634258636?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:58","pubTimestamp":1778533088,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics Inc  expected to post a loss of45cents a share - Earnings Preview Vivos Therapeutics Inc VVOS.OQ VVOS.O is expected to  show a rise in quarterly revenue when it reports  results on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O2K7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629075564","title":"Vivos Therapeutics Faces Nasdaq Listing Compliance Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2629075564","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629075564?lang=en_us&edition=fundamental","pubTime":"2026-04-23 05:03","pubTimestamp":1776891811,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics ( ($VVOS) ) has provided an update. On April 17, 2026, Vivos Therapeutics, Inc. disclosed that Nasdaq had notified the company i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-faces-nasdaq-listing-compliance-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-faces-nasdaq-listing-compliance-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS","NQmain","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629078055","title":"Vivos Therapeutics gets Nasdaq notice for failing minimum stockholders’ equity rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2629078055","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629078055?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:42","pubTimestamp":1776890530,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics received Nasdaq notice on April 17, 2026 for failing to meet Listing Rule 5550 minimum stockholders’ equity requirement.Stockholders’ equity was negative USD 1.55 million as of Dec. 31, 2025, below USD 2.5 million threshold.Company must submit compliance plan by June 1, 2026; Nasdaq could grant extension through Oct. 14, 2026 if plan is accepted.Two first-quarter equity financings raised USD 6.8 million in gross proceeds, including a USD 4.6 million warrant exercise inducement.Failure to regain compliance could trigger delisting determination; hearing request would stay delisting while Nasdaq panel reviews plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL5chb9y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629012828","title":"Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2629012828","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629012828?lang=en_us&edition=fundamental","pubTime":"2026-04-22 18:09","pubTimestamp":1776852540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VVOS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2026 06:09 ET (10:09 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628920053","title":"Vivos Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2628920053","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628920053?lang=en_us&edition=fundamental","pubTime":"2026-04-17 23:04","pubTimestamp":1776438240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VVOS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 17, 2026 11:04 ET (15:04 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628023182","title":"Analysts Conflicted on These Healthcare Names: Vivos Therapeutics (VVOS), Certara (CERT) and Option Care Health (OPCH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628023182","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628023182?lang=en_us&edition=fundamental","pubTime":"2026-04-17 22:00","pubTimestamp":1776434434,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vivos Therapeutics (VVOS), Certara (CERT) and Option Care Health ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-vivos-therapeutics-vvos-certara-cert-and-option-care-health-opch-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-vivos-therapeutics-vvos-certara-cert-and-option-care-health-opch-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4137","LU0012050646.USD","HCSG","BK4196","XLV","CERT","BK4585","VVOS","LABU","LU0029874061.USD","LU0106261612.USD","LU2065731478.USD","BK4581","LU0128526141.USD","BK4167","OPCH","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628559202","title":"Vivos Therapeutics price target lowered to $2.50 from $7 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2628559202","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628559202?lang=en_us&edition=fundamental","pubTime":"2026-04-17 21:52","pubTimestamp":1776433937,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Vivos Therapeutics (VVOS) to $2.50 from $7 and keeps a Buy rating on the shares following the 20...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vivos-therapeutics-price-target-lowered-to-2-50-from-7-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vivos-therapeutics-price-target-lowered-to-2-50-from-7-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628102204","title":"Vivos Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $2.5 From $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2628102204","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628102204?lang=en_us&edition=fundamental","pubTime":"2026-04-17 21:46","pubTimestamp":1776433574,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nAZN4SREQ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628406022","title":"Vivos Therapeutics Balances Growth Hopes With Cash Strain","url":"https://stock-news.laohu8.com/highlight/detail?id=2628406022","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628406022?lang=en_us&edition=fundamental","pubTime":"2026-04-17 08:01","pubTimestamp":1776384114,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics, Inc. (($VVOS)) has held its Q4 earnings call. Read on for the main highlights of the call. Vivos Therapeutics’ latest earnings ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-balances-growth-hopes-with-cash-strain?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-balances-growth-hopes-with-cash-strain?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627230541","title":"Vivos Therapeutics Q4 EPS $(0.58) Misses $(0.48) Estimate, Sales $3.824M Miss $6.447M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2627230541","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627230541?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:25","pubTimestamp":1776284750,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.48) by 20.83 percent. This is a 107.14 percent decrease over losses of $(0.28) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/04/51845490/vivos-therapeutics-q4-eps-0-58-misses-0-48-estimate-sales-3-824m-miss-6-447m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vivos Therapeutics Q4 EPS $(0.58) Misses $(0.48) Estimate, Sales $3.824M Miss $6.447M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627230871","title":"Vivos Therapeutics FY25 net loss widens to $21.2 million; revenue rises 16% to $17.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2627230871","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627230871?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:20","pubTimestamp":1776284420,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics posted a net loss of $21.2 million for full-year 2025, widening from $11.1 million.Operating loss widened to $19.9 million as operating expenses climbed to $30.4 million.Management cited higher sleep testing services and contribution from two Nevada locations of The Sleep Center of Nevada, offset by a wind-down in VIP enrollment revenue.CEO Kirk Huntsman said cost-savings initiatives and a strengthened capital structure support a goal of cash flow positive operations by end of this year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL9GdZHj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014013.SGD","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2W23.USD","BK4196","BK4588","LU2210149790.SGD","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","BK4112","IE00B3QW5Z07.USD","VVOS","IE00B64PRP62.GBP","BK4585","NDAQ","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627308662","title":"Vivos Therapeutics Reports Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2627308662","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627308662?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:20","pubTimestamp":1776284400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA7VX36C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VVOS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627282379","title":"Vivos Therapeutics to report full-year results, host investor conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2627282379","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627282379?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:45","pubTimestamp":1776257115,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics plans to release full-year 2025 financial results Wednesday, April 15, 2026.Management will host conference call at 5:00 p.m. ET April 15, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL1hv4Km:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","BK4588","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4112","IE00BN0W2W23.USD","BK4585","VVOS","NDAQ","BK4196","IE00BKPKM429.USD","SG9999014021.USD","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627628287","title":"Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2627628287","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627628287?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:45","pubTimestamp":1776257100,"startTime":"0","endTime":"0","summary":"Call scheduled for today, Wednesday, April 15, 2026, at 5:00 pm ETLITTLETON, Colo., April  15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (\"Vivos\" or the \"Company\") (NASDAQ: VVOS), a leading me","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/15/3274457/0/en/Vivos-Therapeutics-Schedules-Release-of-Full-Year-2025-Financial-Results-and-Conference-Call.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARE","BK4196","BK4211","VVOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626314382","title":"Vivos Therapeutics says V-Co Investors 3 files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2626314382","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626314382?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:55","pubTimestamp":1775854502,"startTime":"0","endTime":"0","summary":"V-Co Investors 3 reported initial beneficial ownership in Vivos Therapeutics on Form 3 tied to event date March 31, 2026.Filing shows direct ownership of 1,353,625 shares of common stock.Investor also reported pre-funded warrants exercisable for 429,957 shares at USD 0.0001 per share.Additional holdings include Series A warrants for 1,783,582 shares at USD 1.09, expiring March 31, 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL3YNv64:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625955855","title":"Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2625955855","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625955855?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:45","pubTimestamp":1775565900,"startTime":"0","endTime":"0","summary":"Private Placement Funds Operations as Vivos’ Medical Affiliation Model Begins to Take HoldLITTLETON, Colo., April  07, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (\"Vivos\" or the \"Company\") (NAS","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/07/3269171/0/en/Vivos-Therapeutics-Completes-Private-Placement-with-Existing-Private-Equity-Investor-New-Seneca-Partners.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARE","BK4196","EQR","VVOS","BK4588","BK4585","BK4215","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625162262","title":"Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2625162262","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625162262?lang=en_us&edition=fundamental","pubTime":"2026-04-06 13:33","pubTimestamp":1775453580,"startTime":"0","endTime":"0","summary":"U.S. stocks mixed, Cheer Holding announces reverse stock split, Vivos Therapeutics gains investor stake, Quhuo Ltd. reports loss.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/06/Broadcom--Kaufbeuren--Germany---April-26.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/06/Broadcom--Kaufbeuren--Germany---April-26.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/04/51651964/broadcom-vivos-therapeutics-and-3-stocks-to-watch-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/04/51651964/broadcom-vivos-therapeutics-and-3-stocks-to-watch-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0080751232.USD","IE00BFSS7M15.SGD","LU2430703178.SGD","LU2125154935.USD","LU2108987350.USD","LU0354030438.USD","IE00BDGV0183.EUR","IE00BVYPNP33.GBP","IE00BKVL7J92.USD","BK4588","LU1778281490.HKD","LU0310799852.SGD","LU2272731600.USD","LU0109391861.USD","IE00BMPRXN33.USD","LU0345770993.USD","LU0820562030.AUD","LU0320765646.SGD","LU0011850046.USD","LU2089985449.USD","IE00B5949003.HKD","IE00BMPRXQ63.HKD","LU0689472784.USD","AVGU","LU1951200564.SGD","LU1551013342.USD","BK4196","IE00BMPRXR70.SGD","SGXZ81514606.USD","LU1670628061.USD","IE00BVYPNW00.USD","LU2250418816.HKD","LU2065171402.SGD","LU2458330169.SGD","LU0256863902.USD","IE00BJJMRY28.SGD","LU2244417387.USD","LU2750360997.AUD","LU2041044095.USD","LU2211814178.USD","LU2237957902.USD","LU0061474960.USD","LU1917777945.USD","LU0476273544.USD","BK4581","LU2168563687.JPY","LU1732800096.USD","LU2430703095.HKD","IE00BWXC8680.SGD","BK4585","SG9999015945.SGD","LU2237443622.USD","LU0640476718.USD","LU2720916845.USD","LU1989772840.SGD","LU1244550494.USD","LU0719512351.SGD","LU0943347566.SGD","LU1951198990.SGD","IE0034235188.USD","LU1244550577.SGD","LU0787776722.HKD","LU2462157665.USD","IE00BJTD4N35.SGD","LU1732799900.SGD","LU2023250843.SGD","LU2272731865.HKD","LU0444973449.USD","LU2106854487.HKD","IE00BLSP4239.USD","BK4141","LU0154236417.USD","LU1935043536.SGD","LU2764263203.CNY","LU1232071149.USD","LU0234572021.USD","SG9999001424.SGD","IE00BMCWC346.EUR","LU2461242641.AUD","LU0354030511.USD","LU0082616367.USD","IE00B775SV38.USD","LU0048584097.USD","IE00BKPKM429.USD","LU1035775433.USD","VVOS","LU2237443549.SGD","LU2242649171.HKD","LU1989764748.USD","LU0211327993.USD","LU0661504455.SGD","LU2487616109.SGD","LU2458330243.SGD","LU0472753341.HKD","LU2272731782.SGD","LU2211815571.USD","LU1366333091.USD","LU1267930730.SGD","LU2360032135.SGD","SG9999003800.SGD","LU2471134879.HKD","LU1670711123.USD","LU2242650005.HKD","LU1935042991.SGD","LU2505996681.GBP","LU1003077747.HKD","LU2360106780.USD","LU1868836914.USD","IE00BBT3K403.USD","LU2286300806.USD","LU1934455277.USD","LU1629891620.HKD","LU2750360641.GBP","LU0820561818.USD","LU0198837287.USD","IE00B1BXHZ80.USD","IE00BJTD4V19.USD","LU0234570918.USD","LU2265009873.SGD","IE00BQXX3C00.GBP","LU0127658192.USD","BK4515","LU0203347892.USD","LU2125154778.USD","LU2065170008.USD","LU1989772923.USD","LU0203201768.USD","LU1670710661.SGD","IE0004445239.USD","LU0316494557.USD","LU2168564149.EUR","LU0081259029.USD","LU1815333072.USD","LU1720051017.SGD","SGXZ23171101.USD","AVGO","LU0965509101.SGD","LU0109392836.USD","LU0444971666.USD","BK4598","IE00BFSS8Q28.SGD","LU0053666078.USD","LU1992135472.HKD","LU1674673428.USD","LU1988902786.USD","SG9999015978.USD","LU1623119135.USD","IE00BVYPNV92.GBP","LU0348723411.USD","LU0979878070.USD","LU0096364046.USD","LU1868836591.USD","LU2237443895.HKD","LU2355687059.USD","LU2357305700.SGD","LU0056508442.USD","BK4543","LU0345769631.USD","SG9999011175.SGD","LU0289739343.SGD","LU1691799644.USD","LU2023250330.USD","LU0096362180.USD","LU0417517546.SGD","LU0964807845.USD","LU0786609619.USD","LU2087625088.SGD","LU1316542783.SGD","IE00B19Z9P08.USD","LU1992135399.USD","LU2168564222.USD","IE00BKDWB100.SGD","LU1242518857.USD","LU0289961442.SGD","IE0009356076.USD","LU0965509283.SGD","LU2543165471.USD","LU2065171311.SGD","LU2403377893.USD","LU0784385170.HKD","LU1914381329.SGD","LU1127390331.HKD","IE00B3PB1722.GBP","LU0097036916.USD","LU1548497426.USD","LU0251132253.USD","LU0210536198.USD","LU2471134952.CNY","AVGX","LU1989764664.SGD","LU1064131342.USD","LU0823434583.USD","LU1935043023.USD","BK4512","LU0215105999.USD","LU1814569148.SGD","IE00BVYPNQ40.USD","LU0784383803.USD","LU2361044865.SGD","IE00B775H168.HKD","LU2896262040.SGD","LU1974910355.USD","LU2931357623.SGD","LU0210533765.USD","LU0683600562.USD","BK4612","LU1934455863.HKD","LU0820561909.HKD","LU2764262908.HKD","LU0069063385.USD","LU1037948541.HKD","LU2420271590.USD","LU0689626769.HKD","IE00B42XCP33.USD","BK4533","LU2237443465.HKD","SGXZ51526630.SGD","IE00BJJMRX11.SGD","LU2505996509.AUD","LU0345770308.USD","SG9999002224.SGD","LU0861579265.USD","LU1366192091.USD","IE00BGHQF631.EUR","LU2417539215.USD","LU0738911758.USD","IE00B7KXQ091.USD","LU2236285917.USD","LU2347655156.SGD","LU0868494617.USD","LU2168564065.EUR","LU0238689110.USD","LU0823434740.USD","IE00BQXX3F31.USD","IE00BZ9MQY76.HKD","AVGW","LU1244550221.USD","LU1670627923.USD","LU2264538146.SGD","LU0320765059.SGD","LU0642271901.SGD","LU2756315664.SGD","SGXZ99366536.SGD","IE00BK4W5L77.USD","LU1280957306.USD","LU0256863811.USD","IE00B19Z9Z06.USD","LU2746668461.USD","LU2430703251.USD","LU2361044949.HKD","LU2247934214.USD","LU0795875086.SGD","LU0187121727.USD","LU1720051108.HKD","LU0942090050.USD","LU2133065610.SGD","LU0225283273.USD","LU0985320562.USD","IE00B4JS1V06.HKD","LU0957808578.USD","LU1674673691.USD","LU1868837136.USD","LU0726765562.USD","LU0170899867.USD","LU2756315318.SGD","LU2360108059.USD","LU2473716301.USD","LU1923623000.USD","LU2063271972.USD","BK4554","LU2298321311.HKD","LU1153585028.USD","LU2237443978.SGD","BK4605","LU1242518931.SGD","LU0006306889.USD","LU2237957811.SGD","LU1815336760.USD","IE00BQXX3D17.EUR","LU0061475181.USD","LU0210528500.USD","LU0912757837.SGD","IE0004445015.USD","LU2361045086.USD","LU0345768153.USD","LU2054465674.USD","LU2213496289.HKD","LU2065169927.USD","LU2592432038.USD","LU0353189763.USD","LU0345768740.USD","LU1301847155.USD","LU0203345920.USD","LU1037948897.HKD","LU0079474960.USD","IE0005OL40V9.USD","LU0545039389.USD","SG9999001440.SGD","LU2168564495.EUR","LU0466842654.USD","LU2860962120.EUR","LU1868836757.USD","LU2322448791.USD","IE0034235303.USD","AVS","LU0672654240.SGD","LU0708995401.HKD","LU0795875169.SGD","LU1868837300.USD","LU0203202063.USD","LU1670710588.SGD","LU0274383776.USD","IE00BYV24P56.USD","IE0001KFT4U8.USD","LU0124676726.USD","LU0511384066.AUD","IE00B3S45H60.SGD","LU0957791311.USD","LU2764263039.SGD","LU2602419157.SGD","LU2456880835.USD","LU0949170426.SGD","IE00BZ1G4Q59.USD","LU2322448957.HKD","LU1934455194.USD","LU0211328371.USD","LU0345769128.USD","LU1162221912.USD","LU2083900584.USD","LU2023250504.SGD","AVGG","LU2237438978.USD","LU0965508806.USD","LU2279689827.SGD","LU0949170772.SGD","SG9999004303.SGD","LU0889565833.HKD","LU1804176565.USD","LU0353189680.USD","LU1145028129.USD","SG9999015952.SGD","LU2237443382.USD","LU2746668974.SGD","AVL","LU1670711040.USD","IE00BK4W5M84.HKD","IE00BGHQDM52.EUR","LU1852331112.SGD","BK4551","SG9999015986.USD","LU1803068979.SGD","SG9999002232.USD","IE00B894F039.SGD","IE00BN8TJ469.HKD","LU2347655073.USD","BK4575","LU0553294199.USD","LU0965509010.AUD","LU1267930490.SGD","LU0784385840.USD","LU1551013425.SGD","IE00BN29S564.USD","LU1935042215.USD","LU1323610961.USD","LU0323591593.USD","LU0106261372.USD","LU2092937221.SGD","LU2471134523.USD","LU1712237335.SGD","LU2471134796.USD","LU0057025933.USD","LU2463028550.USD","LU1935042488.USD","LU1069344957.HKD","LU0784384876.USD","BK4566","IE00BLSP4452.SGD","IE00BJLML261.HKD","LU1642822529.SGD","IE00B1XK9C88.USD","LU0157215616.USD","LU0868494708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624664176","title":"Vivos Therapeutics Completes Private Placement to Bolster Liquidity","url":"https://stock-news.laohu8.com/highlight/detail?id=2624664176","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624664176?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:35","pubTimestamp":1775248538,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics ( ($VVOS) ) has issued an announcement. On March 31, 2026, Vivos Therapeutics, Inc. completed a private placement with V-Co Inve...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-completes-private-placement-to-bolster-liquidity?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-completes-private-placement-to-bolster-liquidity?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","VVOS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vivos.com","stockEarnings":[{"period":"1week","weight":-0.1351},{"period":"1month","weight":-0.3851},{"period":"3month","weight":-0.6209},{"period":"6month","weight":-0.7462},{"period":"1year","weight":-0.7642},{"period":"ytd","weight":-0.7049}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0817},{"period":"6month","weight":0.1147},{"period":"1year","weight":0.2431},{"period":"ytd","weight":0.0832}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.205284},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.068873},{"month":3,"riseRate":0,"avgChangeRate":-0.209794},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.183475},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.086071},{"month":6,"riseRate":0.6,"avgChangeRate":0.052001},{"month":7,"riseRate":0.4,"avgChangeRate":-0.104292},{"month":8,"riseRate":0.6,"avgChangeRate":0.170604},{"month":9,"riseRate":0,"avgChangeRate":-0.252021},{"month":10,"riseRate":0.2,"avgChangeRate":-0.105489},{"month":11,"riseRate":0.4,"avgChangeRate":1.251693},{"month":12,"riseRate":0.2,"avgChangeRate":-0.12992}],"exchange":"NASDAQ","name":"Vivos Therapeutics","nameEN":"Vivos Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vivos Therapeutics(VVOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vivos Therapeutics,VVOS,Vivos Therapeutics股票,Vivos Therapeutics股票老虎,Vivos Therapeutics股票老虎国际,Vivos Therapeutics行情,Vivos Therapeutics股票行情,Vivos Therapeutics股价,Vivos Therapeutics股市,Vivos Therapeutics股票价格,Vivos Therapeutics股票交易,Vivos Therapeutics股票购买,Vivos Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vivos Therapeutics(VVOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}